{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:05:53Z","timestamp":1774065953790,"version":"3.50.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Widespread application of massively parallel sequencing has resulted in recognition of clonal hematopoiesis in various clinical settings and on a relatively frequent basis. Somatic mutations occur in individuals with normal blood counts, and increase in frequency with age. The genes affected are the same genes that are commonly mutated in overt myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This phenomenon is referred to as clonal hematopoiesis of indeterminate potential (CHIP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>In this review, we explore the diagnostic and clinical implications of clonal hematopoiesis. In addition to CHIP, clonal hematopoiesis may be seen in patients with cytopenia who do not otherwise meet criteria for hematologic malignancy, a condition referred to as clonal cytopenia of undetermined significance (CCUS). Distinguishing CHIP and CCUS from overt myeloid neoplasm is a challenge to diagnosticians due to the overlapping mutational landscape observed in these conditions. We describe helpful laboratory and clinical features in making this distinction. CHIP confers a risk of progression to overt hematologic malignancy similar to other premalignant states. CHIP is also associated with a proinflammatory state with multisystem implications and increased mortality risk due to cardiovascular events. The current approach to follow up and management of patients with clonal hematopoiesis is described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Nuanced understanding of clonal hematopoiesis is essential for diagnosis and clinical management of patients with hematologic conditions. Further data are needed to more accurately predict the natural history and guide management of these patients with respect to both malignant progression as well as nonhematologic sequelae.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvab105","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T03:19:02Z","timestamp":1622517542000},"source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis"],"prefix":"10.1093","author":[{"given":"Afaf","family":"Osman","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, University of Utah, and Huntsman Cancer Institute, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay L","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"2021071506120034400_hvab105-B1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B2","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B6","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol Oncol"},{"key":"2021071506120034400_hvab105-B8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrg3354","article-title":"DNA methylation: roles in mammalian development","volume":"14","author":"Smith","year":"2013","journal-title":"Nat Rev Genet"},{"key":"2021071506120034400_hvab105-B9","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"2021071506120034400_hvab105-B10","doi-asserted-by":"crossref","first-page":"2:264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"2021071506120034400_hvab105-B11","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-012-1565-4","article-title":"Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification","volume":"92","author":"Font","year":"2013","journal-title":"Ann Hematol"},{"key":"2021071506120034400_hvab105-B13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-014-2252-4","article-title":"Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts","volume":"94","author":"Font","year":"2015","journal-title":"Ann Hematol"},{"key":"2021071506120034400_hvab105-B14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","article-title":"Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors","volume":"7","author":"Steensma","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"2021071506120034400_hvab105-B15","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B16","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B19","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2021071506120034400_hvab105-B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.leukres.2017.01.027","article-title":"Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia","volume":"56","author":"Patel","year":"2017","journal-title":"Leuk Res"},{"key":"2021071506120034400_hvab105-B23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B25","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2020-143813","article-title":"Driver mutation acquisition in utero and childhood followed by lifelong clonal evolution underlie myeloproliferative neoplasms","volume":"136","author":"Williams","year":"2020","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"2021071506120034400_hvab105-B27","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"2021071506120034400_hvab105-B28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11899-018-0473-7","article-title":"Hereditary myelodysplastic syndrome and acute myeloid leukemia: diagnosis, questions, and controversies","volume":"13","author":"Akpan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2021071506120034400_hvab105-B29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"2021071506120034400_hvab105-B30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","article-title":"Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations","volume":"559","author":"Loh","year":"2018","journal-title":"Nature"},{"key":"2021071506120034400_hvab105-B31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.2019001793","article-title":"Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality","volume":"135","author":"Hansen","year":"2020","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2021071506120034400_hvab105-B33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","article-title":"Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host","volume":"557","author":"Meisel","year":"2018","journal-title":"Nature"},{"key":"2021071506120034400_hvab105-B34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2021071506120034400_hvab105-B35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"2021071506120034400_hvab105-B36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"2021071506120034400_hvab105-B37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021071506120034400_hvab105-B38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021071506120034400_hvab105-B39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"2021071506120034400_hvab105-B40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021071506120034400_hvab105-B41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2021071506120034400_hvab105-B42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2018-99-118288","article-title":"Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and convergent macrophage phenotypes in mice","volume":"132","author":"Rauch","year":"2018","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"2021071506120034400_hvab105-B44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"2021071506120034400_hvab105-B45","first-page":"A15111","article-title":"Abstract 15111: TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis","volume":"138","author":"Svensson","year":"2018","journal-title":"Circulation"},{"key":"2021071506120034400_hvab105-B46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2008.07258.x","article-title":"The JAK2 V617F mutation and thrombosis","volume":"143","author":"Austin","year":"2008","journal-title":"Br J Haematol"},{"key":"2021071506120034400_hvab105-B47","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through beta1\/beta2 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J Clin Invest"},{"key":"2021071506120034400_hvab105-B48","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021071506120034400_hvab105-B49","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation","volume":"41","author":"Mas-Peiro","year":"2020","journal-title":"Eur Heart J"},{"key":"2021071506120034400_hvab105-B50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2021071506120034400_hvab105-B51","author":"Bick","year":"2020"},{"key":"2021071506120034400_hvab105-B52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ajcp\/95.1.63","article-title":"The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation","volume":"95","author":"Karcher","year":"1991","journal-title":"Am J Clin Pathol"},{"key":"2021071506120034400_hvab105-B53","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.3390\/cancers12071992","article-title":"Clinico-biological features and clonal hematopoiesis in patients with severe COVID-19","volume":"12","author":"Duployez","year":"2020","journal-title":"Cancers"},{"key":"2021071506120034400_hvab105-B54","author":"Bolton","year":"2020"},{"key":"2021071506120034400_hvab105-B55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.11.008","article-title":"Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients","volume":"80","author":"Zhang","year":"2019","journal-title":"Exp Hematol"},{"key":"2021071506120034400_hvab105-B56","first-page":"1675","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Young","year":"2015","journal-title":"N Engl J Med"},{"key":"2021071506120034400_hvab105-B57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021071506120034400_hvab105-B58","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/leu.2016.63","article-title":"Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation","volume":"30","author":"Gondek","year":"2016","journal-title":"Leukemia"},{"key":"2021071506120034400_hvab105-B59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/leu.2013.278","article-title":"Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation","volume":"28","author":"Yasuda","year":"2014","journal-title":"Leukemia"},{"key":"2021071506120034400_hvab105-B60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2017.104","article-title":"Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient","volume":"31","author":"Herold","year":"2017","journal-title":"Leukemia"},{"key":"2021071506120034400_hvab105-B61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1126\/scitranslmed.aax6249","article-title":"Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation","volume":"12","author":"Wong","year":"2020","journal-title":"Sci Transl Med"},{"key":"2021071506120034400_hvab105-B62","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood.2019003079","article-title":"Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Boettcher","year":"2020","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2017-01-764951","article-title":"Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias","volume":"130","author":"Gibson","year":"2017","journal-title":"Blood"},{"key":"2021071506120034400_hvab105-B64","first-page":"1623","article-title":"What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics","volume":"136","author":"Steensma","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/advance-article-pdf\/doi\/10.1093\/clinchem\/hvab105\/38984497\/hvab105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/advance-article-pdf\/doi\/10.1093\/clinchem\/hvab105\/38984497\/hvab105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T06:12:59Z","timestamp":1626329579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/advance-article\/doi\/10.1093\/clinchem\/hvab105\/6321659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":64,"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvab105","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"article-number":"hvab105"}}